Core Viewpoint - Jyong Biotech Ltd. is advancing its plant-derived drug MCS-2, which has completed Phase III clinical trials for benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), highlighting its competitive advantages and potential clinical benefits [1][2]. Group 1: Clinical Development - MCS-2 is the only oral botanical new drug globally to complete Phase III clinical trials for BPH, with four trials conducted in the U.S. and Taiwan, including pivotal trials and open-label extensions [2][4]. - The trials involved over 200 urologists across 27 centers in 19 U.S. states and more than 70 urologists in 12 major hospitals in Taiwan, establishing a robust physician network for future commercialization [3][4]. Group 2: Safety and Efficacy - MCS-2 has demonstrated excellent safety across all Phase III trials, with no serious adverse events reported, supporting its long-term use [4]. - The drug has undergone rigorous scientific validation, adhering to FDA guidelines and completing over ten international toxicology studies [4]. Group 3: Intellectual Property - Jyong Biotech holds global patent protection for its core technology, enhancing bioavailability and enabling various formulations, including oral and injectable forms [5]. Group 4: Market Potential - BPH/LUTS affects hundreds of millions of men globally, with current treatments often leading to side effects and drug resistance, creating a significant unmet need for safe, long-term solutions [6][7]. - The aging global population and increasing healthcare demand present substantial growth potential for prostate disease treatment and prevention [7]. Group 5: Company Commitment - Jyong Biotech emphasizes innovation and R&D, adhering to international standards for quality and regulatory compliance, positioning itself for global market entry and partnerships [8][11]. - The company aims to develop first-class innovative drugs to meet health needs and enhance its reputation as a valuable business organization [11].